News

Patients with EGFR exon 20 insertion–mutated NSCLC treated with amivantamab plus chemotherapy experienced an extension in the time to treatment discontinuation and subsequent therapy.

Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.

Patients with advanced hepatocellular carcinoma treated with nivolumab plus ipilimumab had an improvement in overall survival compared with standard-of-care TKIs.

Patients with microsatellite instability high primary advanced or recurrent endometrial cancer derived a significant survival benefit when treated with dostarlimab plus chemotherapy.

Patients with non–small cell lung cancer treated with targeted therapies experienced an overall survival benefit.

Progression-free and overall survival benefits were obtained with MRD-guided ibrutinib plus venetoclax when compared with fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Amanda Duck, PA-C, RD, held a discussion during a Community Case Forum on the progress made in using immunotherapy to treat patients with advanced endometrial cancer and the creativity sometimes needed to address adverse events.

The safety label for fluorouracil products will now include information about the agent’s use in patients with dihydropyrimidine dehydrogenase deficiency.

An expert discusses how radiation may improve quality of life in patients with rectal cancer, in addition to when radiation or surgery could be omitted.

Patients with platinum-resistant or -refractory epithelial ovarian cancer treated with olaparib plus cediranib did not experience improvements in PFS and OS compared with chemotherapy.

Venetoclax provided long-lasting responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Further evidence strengthens the support of mirvetuximab soravtansine as a new standard of care for folate receptor-alpha—positive ovarian cancer resistant to platinum chemotherapy.

Accelerated approval was granted by the FDA to ponatinib plus chemo for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

A next-generation stool DNA test had higher sensitivity for CRC and advanced precancerous lesions but lower specificity for advanced neoplasia compared with a fecal immunochemical test.

An expert explained the importance of having strong communication skills not only for all patients with cancer, but especially for those who received a terminal diagnosis.

The Oncologic Drugs Advisory Committee of the FDA unanimously voted in favor of ciltacabtagene autoleucel for the treatment of early relapsed/refractory myeloma.

Compared with placebo, first-line niraparib maintenance was not linked with worsened health-related quality of life outcomes in patients with advanced ovarian cancer.

The FDA granted an orphan drug designation to avutometinib either alone or in combination with defactinib for recurrent low-grade serous ovarian cancer.

The benefits of imetelstat outweigh the risks for anemia treatment in lower-risk myelodysplastic syndrome, according to a vote by the FDA’s Oncologic Drugs Advisory Committee.

Accelerated approval has been granted by the FDA to lisocabtagene maraleucel for the treatment of certain patients with relapsed/refractory CLL or SLL.

Tislelizumab-jsgr (Tevimbra) has been approved for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) among adult patients who have previously received systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.

Oncology nurses can inform patients about the probability of identifying advanced neoplasia using stool-based screening tools.

The use of nivolumab plus chemotherapy as a standard frontline treatment has been supported by recent data from the phase 3 CheckMate 649 trial for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Treatment for relapsed or refractory diffuse large B-cell lymphoma with brentuximab vedotin, lenalidomide, and rituximab contributed to an improvement in overall survival vs lenalidomide/rituximab/placebo.

With the progress made with ADCs, there is interest in moving these agents up in the treatment paradigm for HR-positive/HER2-negative breast cancer.

Simple hysterectomy was shown to reduce the incidence of urinary incontinence vs radical hysterectomy for low-risk cervical cancer.

Based on results from a post hoc analysis, researchers found that lurbinectedin was more effective and less toxic than topotecan for the treatment of small cell lung cancer.

In a 16-to-2 vote, the FDA's Medical Imaging Drugs Advisory Committee voted in support of the benefit-risk profile of Lumisight to detect cancerous tissue during breast conservation surgery.

Cancer teams, including oncology nurses, can make conscious choices to potentially alleviate the disparities that persist in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.